Anti-Mouse/Human VLA-4/CD49d Antibody (PS/2) 

Anti-Mouse/Human VLA-4/CD49d Antibody (PS/2) is an anti-mouse/human VLA-4/CD49d IgG2b monoclonal antibody. Anti-Mouse/Human VLA-4/CD49d Antibody (PS/2) can reduce VLA-4 positive cells. Anti-Mouse/Human VLA-4/CD49d Antibody (PS/2) can inhibit the migration of Tc1 cells to tumors. Anti-Mouse/Human VLA-4/CD49d Antibody (PS/2) inhibits the retention of leukemia cells in the spleen and bone marrow by blocking VLA-4. Anti-Mouse/Human VLA-4/CD49d Antibody (PS/2) can be used for research on inflammation conditions and cancer such as experimental autoimmune encephalomyelitis (EAE), melanoma and leukemia^[1][2][3].

Rat IgG2b kappa

Rat IgG2b kappa, Isotype Control

Human/Mouse

Anti-Mouse/Human VLA-4/CD49d Antibody (PS/2) (20 μg/mL, 15 min) significantly inhibits the adhesion of Tc1 cells to VCAM-1^[2].

MedChemExpress (MCE) has not independently confirmed the accuracy of these methods. They are for reference only.

Anti-Mouse/Human VLA-4/CD49d Antibody (PS/2) (0.1 mg, i.p., once every other day, from day 4 to day 14) significantly reduces the incidence of diseases in female BALB/c mice with a virus induced experimental autoimmune encephalomyelitis (EAE) model^[1].
Anti-Mouse/Human VLA-4/CD49d Antibody (PS/2) (150 μg, i.v., single dose) significantly inhibits the migration of Tc1 cells to intracranial tumors in C57BL/6 mice bearing M05 tumors^[2].
Anti-Mouse/Human VLA-4/CD49d Antibody (PS/2) (10 mg/kg, i.p., twice a week, for 5 weeks) significantly reduces tumor cells in the spleen and bone marrow in wild type C57BL/6J mice with a chronic lymphocytic leukemia (CLL) model^[3].

MedChemExpress (MCE) has not independently confirmed the accuracy of these methods. They are for reference only.

16401  [NCBI]

Q00651

in vivo VLA-4 neutralization; in vitro VLA-4 neutralization; Flow cytometry

Unconjugated

The product can be reconstituted/diluted with sterile PBS or saline.

150 kDa

Liquid

Colorless to light yellow

[Anti-Mouse/Human VLA-4/CD49d Antibody (PS/2)]

Please refer to the lot-specific COA for specific buffer information.

Please store the product under the recommended conditions in the Certificate of Analysis.

• 
  Flow cytometric analysis of 1×10⁶ Jurkat cells labelling VLA-4 (red) with Anti-Mouse/Human VLA-4 Antibody (HY-P990144). Cells were fixed with 4% paraformaldehyde and permeabilised with 90% methanol. Then stained with the primary antibody at 1/200 dilution for an hour at 4℃. Alexa Goat Anti-Rabbit IgG H&L (AF488) (HY-P8002) was used as the secondary antibody at 1/1,000 dilution for 30 minutes at 4℃. Rat IgG2b kappa Isotype Control (HY-P990682, blue) was used as the isotype control.

• [1]. Soilu-Hänninen M, et al. Therapy with antibody against leukocyte integrin VLA-4 (CD49d) is effective and safe in virus-facilitated experimental allergic encephalomyelitis. J Neuroimmunol. 1997 Jan;72(1):95-105.  [Content Brief]

  [2]. Sasaki K, et al. Preferential expression of very late antigen-4 on type 1 CTL cells plays a critical role in trafficking into central nervous system tumors. Cancer Res. 2007 Jul 1;67(13):6451-8.  [Content Brief]

  [3]. Szenes E, et al. TCL1 transgenic mice as a model for CD49d-high chronic lymphocytic leukemia. Leukemia. 2020 Sep;34(9):2498-2502.  [Content Brief]